Tech Translator

Li Hao also listened to Director Du Xianyu's explanation. At the same time, he confirmed with the real technology and alien technology he learned.

We know that the current organ manufacturing technology has completed most of the pre-processing technologies. The final attack will be carried out. This is much earlier than his expected technical completion time.

In the past, it was expected that the problem of organ production could be solved in two years, which is very fast.

After breaking through the first core technology in the laboratory, he expects the technology to be completed within a year. Now it seems that the whole organ will have to wait a long time. However, some functional cells have already met the requirements of clinical verification.

A smile appeared on Li Hao's face, and he hurriedly asked Du Xianyu: Director Du, you have successfully completed hematopoietic stem cells, so can you treat leukemia, hemophilia, lymphoma and other diseases now?

If the developed hematopoietic stem cells can solve the incurable diseases that have plagued human beings for many years. The impact of that was too great.

Director Du Xianyu shook his head and said: This is our goal in the future. There are still many technologies that are not yet mature, but the technology for making blood and blood products has matured.

Li Hao immediately extracted the main point of Du Xianyu's director's speech. He then asked: Director Du, you mean that our company's technology is not yet mature, not that it has not yet developed this technology. Does that mean that this technology has been developed?

Du Xianyu said helplessly: We have induced the differentiation of hematopoietic stem cells, and various techniques have been successful.

We did experiments on mice that had been knocked out to have hemophilia. The feasibility of hematopoietic stem cell therapy has been verified.

But it has a high mortality rate of 60%. Such a high mortality rate cannot be used in clinical trials.

Without solving the specific cause of death, we will continue to conduct animal experiments.

Zhou Yunsheng listened to their conversation, she reminded: Director Du, 40% cure rate is already very high for this disease, and the fatality rate of diseases without this technology is 100%.

And your experimental animals, whether the death was caused by the injection of hematopoietic stem cells, or the death caused by the disease. These two points need to be clarified, they represent different meanings.

Don't worry, Mr. Zhou, the medical expert team of our project is constantly analyzing the pathological changes of the experimental animals. We will not fail to notice if we really find something. Du Xianyu replied with a smile.

Li Hao realized that the death rate of this technology should not be so high. He asked directly: Director Du, what is the main reason for the death of the mouse. Even if the mouse was infused with human hematopoietic stem cells, its death rate is not so high.

Immune rejection, there is really no way. We have knocked out the surface antigen of hematopoietic stem cells. But for some unknown reason, it will also cause the immune system of the organism to attack. Du Xianyu said very helplessly.

Hearing this result, Li Hao widened his eyes and asked in puzzlement: You have knocked out the surface antibodies of hematopoietic stem cells. Why don't you use mouse cells to cultivate hematopoietic stem cells, and then conduct experiments.

Our project is organ manufacturing, that is, the industrial production of organs. Our goal is to solve immune rejection. Just like producing industrial products, we can produce exactly the same organs for human transplantation.

Mr. Li, isn't this also your request for our biological laboratory. We have been working hard in this direction. Director Du Xianyu said firmly.

Under Zhou Yunsheng's look at the fool, Li Hao smiled wryly while covering his face. He should have inspected Director Du's technical route long ago. I didn't expect such a big mistake.

You must know that Du Xianyu is a typical stubborn character. It was for the research of human cloning technology, risking the risk of violating the law, and exploring the technology.

He could only explain with a wry smile: Director Du, you have misunderstood me. What I said is the ultimate goal of the project. But now we have very little understanding of life sciences, and we have only just explored the initial stage of human immune function. .

We can't knock out all the proteins on the cell surface, and the cells can't perform functional tasks. In particular, we lack an overall understanding of the immune system, and we are still unable to completely eliminate immune rejection.

The best technical route now is to select the general body of the receptor itself and cultivate it into a complete organ. This way we don't need to think about immune rejection.

Du Xianyu thought carefully for a while, and he said: This method needs to target each different receptor, cultivate his cells from scratch, and induce differentiation.

This process is easily done in our laboratory, but it will definitely have technical applications in the future.

The scientific and technological workers in our project team also have to carry out their own project research and development. It is impossible for me to treat professionals as workers and perform such low-quality work.

We can't hand over this work to other people. Every step requires experienced talents. There are really people who can do this project. Then he is an excellent scientific research assistant. It is a waste of talent to do this kind of repetitive work.

Li Hao directly raised the most critical question: Director Du, I'm talking about using specific human cells to cultivate organs and some functional cells. Can the current technical standards meet the requirements? What will happen when they are implanted in the patient's body? ?

It is to use ordinary people to exceed it, what is the worst result?

Du Xianyu almost didn't think about it, and immediately answered this question: Now we only complete the induced differentiation of hematopoietic stem cells, such as using receptors to induce the differentiation of cells into hematopoietic stem cells.

I can be sure that he will definitely not have a rejection reaction. That is to say, there is no impact on human safety. But whether it can divide and differentiate normally in the body. Since I haven't done experiments, I can't confirm the specific effect.

However, in our experiments on mice, as long as the metabolism is normal, there is no interference from other related diseases. Cells implanted in the body will continue to work normally.

After answering this question, he continued: It's better to let the machine operate the process according to the intelligent program.

Without professional intervention, its success rate is very low. We have only been able to reach 5% after testing.

When tested on hematopoietic stem cells, it differentiates into misshapen cells, or seemingly normal but functionless organs. That is, there is no biological activity.

We deny this technical route because the detection procedure is too troublesome. Until a good detection method is found, this technology has many shortcomings.

Some even tested without the slightest problem. However, when transplanted into living organisms, they cannot exert biological activity.

If the appearance is glamorous, the organ that turns out to be useless is transplanted to the patient. For example, hematopoietic stem cells are okay, but if it is a large organ, it is not a medical malpractice.

Li Hao heard Director Du Xianyu's complaint, and he finally knew where the technical difficulties in their work were.

But he still feels that his technical route is more correct. The general-purpose organs recorded in the library, their implementation methods are very difficult for the current scientific and technological foundation.

Li Hao put forward his own suggestion: Director Du, I think using specific human cells and using instruments to synthesize target organs. This technical route is easier to implement.

With your ability to find assays with living organisms, it's easier than making general-purpose organs.

Du Xianyu also felt that what Li Hao said made sense. He thought carefully for a while, and responded: Then I will redistribute the scientific research power of various project groups. Our main people will continue to explore the cultivation and differentiation of totipotent stem cells.

Just let the medical team and the organ testing project team explore better ways to detect living organs.

As for the study of general-purpose organs, only a few scientific research groups are reserved to explore the technical feasibility.

Li Hao gave a thumbs up and sighed: Director Du's method is very good, and he arranges all kinds of work very well. I am just offering a suggestion. You are an expert in this field, so you can arrange it according to the specific situation of the project.